News Focus
News Focus
icon url

biomaven0

11/16/11 10:12 AM

#14215 RE: adreamer #14213

what's baked in to the current market cap



Ponatinib approval for 3rd-line. 80% chance of rida approval. Nothing for '113 or rida combination therapy.

In terms of near-term catalysts there is the updated data at ASH (unlikely to move the stock much either way) and maybe an Asia partnership.

Peter